Skip to Main Content

Author Details

Ola Myklebost
Institute for Cancer Research, Oslo University Hospital
1983
183
56
Nathan Sheffield (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36656928Heritable defects in telomere and mitotic function selectively predispose to sarcomas.Science2023
37799721The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition.Front Immunol2023
37622176Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential.Mol Oncol2023
35172717miR-486-5p expression is regulated by DNA methylation in osteosarcoma.BMC Genomics2022
35643867Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence.Leukemia2022
35948919Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy.Genome Med2022
34050156Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden.Nat Commun2021
33744765Methylation-dependent SUMOylation of the architectural transcription factor HMGA2.Biochem Biophys Res Commun2021
33690666Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening.PLoS One2021
33745702Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour.Pathology2021
34470667The expressed mutational landscape of microsatellite stable colorectal cancers.Genome Med2021
34310709Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high-throughput germline screening in cancer.Int J Cancer2021
32158531Accurate 3-gene-signature for early diagnosis of liposarcoma progression.Clin Sarcoma Res2020
33348862Cell Fusion of Mesenchymal Stem/Stromal Cells and Breast Cancer Cells Leads to the Formation of Hybrid Cells Exhibiting Diverse and Individual (Stem Cell) Characteristics.Int J Mol Sci2020
32374878Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series.Blood Adv2020
30795553Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.Cells2019
30181068Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.Eur Urol2019
29272339Personal Cancer Genome Reporter: variant interpretation report for precision oncology.Bioinformatics2018
30078998Real-Time Vital Mineralization Detection and Quantification during In Vitro Osteoblast Differentiation.Biol Proced Online2018
29991680Patterns of genomic evolution in advanced melanoma.Nat Commun2018
30097488Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor.Mol Cancer Ther2018
29771965Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples.PLoS One2018
29570692Preclinical Evaluation of Vemurafenib as Therapy for BRAF<sup>V600E</sup> Mutated Sarcomas.Int J Mol Sci2018
29593270Sample-Index Misassignment Impacts Tumour Exome Sequencing.Sci Rep2018
28061772Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report.BMC Cancer2017
28387924High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival.Int J Cancer2017
28385781Monitoring multiple myeloma by quantification of recurrent mutations in serum.Haematologica2017
28539123Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.Genome Med2017
28805158PP2A Regulatory Subunit B55γ is a Gatekeeper of Osteoblast Maturation and Lineage Maintenance.Stem Cells Dev2017
28643781Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma.Nat Commun2017
28848235Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b.Sci Rep2017
28683746Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.Mol Cancer2017
27242894TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients.Front Genet2016
26595521HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.Oncotarget2016
26672768Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.Oncotarget2016
27685995Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene.PLoS One2016
27197245Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.Genome Res2016
27498913Monogenic and polygenic determinants of sarcoma risk: an international genetic study.Lancet Oncol2016
27409346Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.Oncotarget2016
27315524The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report.Clin Sarcoma Res2016
27488532The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma.Cancer Res2016
25794135BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.Blood Cancer J2015
29750616Personalized cancer therapy for soft tissue sarcomas: progress and pitfalls.Per Med2015
26627287Genome sequencing in research requires a new approach to consent.Tidsskr Nor Laegeforen2015
26643872Genomic landscape of liposarcoma.Oncotarget2015
26520668Norwegian Cancer Genomics Consortium: a platform for research on personalized cancer medicine in a public health system.Drug Discov Today2015
25963125Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.Genome Res2015
25623255Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death.Mol Cancer2015
25669981Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA.Oncotarget2015
24403055The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines.Cancer Med2014
  • 1 - 50 of 183

Recommended Authors

Ritu Roy
University of California San Francisco.
Career Start Year 2007
Number of shared co-authors 2
Yuelin J Zhu
National Cancer Institute, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 3
Sven Bilke
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 4
Ru-Fang Yeh
Genentech Inc.
Career Start Year 1999
Number of shared co-authors 2
Benedikt Brors
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 42
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 8
Qing-Rong Chen
Center for Biomedical Informatics and Information Technology
Career Start Year 1996
Number of shared co-authors 10
Agnes Viale
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 3
David Cogdell
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 1
Alexei Protopopov
The University of MD Anderson Cancer Center
Career Start Year 1995
Number of shared co-authors 18
Doris Steinemann
Hannover Medical School
Career Start Year 1994
Number of shared co-authors 10
Yong-Jie Lu
Barts Cancer Institute, Queen Mary University of London
Career Start Year 1993
Number of shared co-authors 29
Nalan Gokgoz
Lunenfeld-Tanenbaum Research Institute
Career Start Year 1993
Number of shared co-authors 13
Javed Khan
Center for Cancer Research, National Cancer Institute
Career Start Year 1993
Number of shared co-authors 23
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 3
Sean M Grimmond
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 22
Eberhard Korsching
Institutet of Bioinformatics, University Hospital of Munster, University of Munster
Career Start Year 1990
Number of shared co-authors 16
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 4
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 1
Suzanne Kamel-Reid
Toronto General Hospital, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 1
Mark A Watson
Washington University School of Medicine
Career Start Year 1987
Number of shared co-authors 1
Jonathan R Pollack
Stanford University School of Medicine
Career Start Year 1987
Number of shared co-authors 3
Peter Lichter
German Cancer Research Center (DKFZ)
Career Start Year 1986
Number of shared co-authors 24
Beat W Sch??fer
Department of Oncology and Children's Research Center, University Children's Hospital
Career Start Year 1985
Number of shared co-authors 20
Jeremy A Squire
University of Sao Paulo
Career Start Year 1982
Number of shared co-authors 6
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 3
Ching C Lau
Baylor College of Medicine
Career Start Year 1982
Number of shared co-authors 13
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year 1982
Number of shared co-authors 14
Webster K Cavenee
Ludwig Institute for Cancer Research, University of California San Diego
Career Start Year 1977
Number of shared co-authors 4
Irene L Andrulis
University of Toronto
Career Start Year 1977
Number of shared co-authors 29

Collaborators

Eivind Hovig
Center for Bioinformatics, University of Oslo
Co-authored papers 33
Daniel Vod??k
Institute for Cancer Research, Oslo University Hospital
Co-authored papers 12
Massimo Serra
IRCCS Istituto Ortopedico Rizzoli
Co-authored papers 9
Sigve Nakken
University of Oslo
Co-authored papers 9
Anne-Lise B??rresen-Dale
Institute for Cancer Research, Oslo University Hospital
Co-authored papers 8
Adrienne M Flanagan
University College London, UCL Cancer Institute
Co-authored papers 6
Patrick S Tarpey
Wellcome Trust Sanger Institute
Co-authored papers 6
Peter J Campbell
Wellcome Sanger Institute
Co-authored papers 5
Kjetil Boye
Oslo University Hospital
Co-authored papers 5
Sakari Knuutila
Co-authored papers 5
Jahn M Nesland
The Norwegian Radium Hospital, Oslo University Hospital
Co-authored papers 4
Michael R Stratton
Wellcome Sanger Institute
Co-authored papers 4
Gunes Gundem
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
David C Wedge
Manchester Cancer Research Centre, University of Manchester
Co-authored papers 4
David M Thomas
Garvan Institute of Medical Research
Co-authored papers 4
Peter Van Loo
The Francis Crick Institute
Co-authored papers 4
Ultan McDermott
Wellcome Sanger Institute
Co-authored papers 4
Serena Nik-Zainal
Early Cancer Institute, University of Cambridge
Co-authored papers 4
Vigdis Nygaard
Institute for Cancer Research, Oslo University Hospital
Co-authored papers 4
Marit Holden
University of Mainz
Co-authored papers 3
Manasa Ramakrishna
Co-authored papers 3
Rosalind A Eeles
The Institute of Cancer Research
Co-authored papers 3
Susanna L Cooke
Institute of Cancer Sciences, University of Glasgow
Co-authored papers 3
Andrea L Richardson
Co-authored papers 3
David E Neal
University of Oxford, John Radcliffe Hospital
Co-authored papers 3
Heidi Lyng
Radiumhospitalet, Oslo University Hosptial
Co-authored papers 3
Sunil R Lakhani
University of Queensland
Co-authored papers 3
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 3
Steve E Humphries
Co-authored papers 3
George Steven Bova
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Co-authored papers 3
Release 1.2